OQROGet OQRO Pro
Insider trade

Enliven Therapeutics (ELVN)Director sold ~$294K

Rahul D. Ballal, Director at Enliven Therapeutics, sold ~$294K of Enliven Therapeutics shares.

~$294K
Approx. value · 10K sh @ $28.17
22K
Holds after · shares reported
Traded
Oct 8, 2024
Filed
Oct 11, 2024

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Sep 27, 2024InsiderCFO sold ~$103K of ELVN shares in the open market
  2. Sep 30, 2024InsiderCFO sold ~$51K of ELVN shares in the open market
  3. Oct 1, 2024Insider · 4 peopleInsiders: 4 sales (~$58K)
  4. Oct 4, 2024Insider · 4 peopleInsiders: 4 sales (~$902K)
  5. Oct 7, 2024Insider · 3 peopleInsiders: 3 sales (~$185K)
  6. Oct 8, 2024 · this disclosureInsiderDirector sold ~$294K of ELVN shares in the open market

What came next

  1. Oct 8, 2024Insider · 2 peopleInsiders: 4 sales (~$742K)
  2. Oct 9, 2024Insider · 2 peopleInsiders: 4 sales (~$1.5M)
  3. Oct 15, 2024InsiderDirector sold ~$35K of ELVN shares in the open market
  4. Oct 18, 2024Insider · 6 peopleInsiders: 7 sales (~$171K)
  5. Oct 28, 2024Insider · 1 personInsiders: 2 sales (~$178K)
  6. Nov 27, 2024Insider · 1 personInsiders: 2 sales (~$131K)
  7. Dec 27, 2024InsiderCFO sold ~$74K of ELVN shares in the open market
  8. Dec 30, 2024InsiderCFO sold ~$20K of ELVN shares in the open market
  9. Jan 3, 2025InsiderCFO sold ~$25K of ELVN shares in the open market
  10. Jan 7, 2025Insider · 1 personInsiders: 4 sales (~$686K)
  11. Jan 27, 2025InsiderCFO sold ~$70K of ELVN shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Enliven Therapeutics

For Enliven Therapeutics, OQRO holds 1 insider filing (SEC Form 4 or Form 144) and 6 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ELVN page.

Other recent filings by Rahul D. Ballal, Director

The full history of Rahul D. Ballal, Director is on the profile page.

How this filing works

Other disclosures at Enliven Therapeutics

Everything OQRO holds on this company is on its ELVN page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data